Notably, inhibitors/antagonists against oncogenes such as tropomyosin receptor kinase (TRK), Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KARS)10, epidermal growth factor receptor (EGFR)/ epidermal growth factor receptor 2 (Her2)11 have been studied by researchers and shed light on potential novel therapeutic strategies for pancreatic cancer. This evidence concerns the gene EGFR and familial pancreatic carcinoma.